References
  1. Lubamba B, Dhooghe B, Noel S, Leal T. Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem. 2012;45:1132–1144.
  2. Boucher RC. An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev. 2002;54:1359–1371.
  3. Ong T, Ramsey BW. New therapeutic approaches to modulate and correct cystic fibrosis transmembrane conductance regulator. Pediatr Clin North Am. 2016; 63:751–764.
  4. Davies JC, Alton EW, Bush A. Cystic fibrosis. Br Med J. 2007; 335(7632):1255–1259.
  5. Spoonhower KA, Davis PB. Epidemiology of cystic fibrosis. Clin Chest Med. 2016;37:1–8.
  6. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N. Engl J Med. 2005;352(19):1992-2001
  7. Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Accurso FJ. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009;155(Suppl. 6):S73–S93.
  8. Lahiri T, Hempstead SE, Brady C, Cannon CL, Clark K, Condren ME, Davis SD. Clinical practice guidelines from the Cystic Fibrosis Foundation for preschoolers with cystic fibrosis. Pediatrics. 2016;137:1–26.
  9. Edmondson C, Davies JC. Current and future treatment options for cystic fibrosis lung disease: Latest evidence and clinical implications. Ther Adv Chronic Dis 2016;7:170–183
  10. Pettit RS, Fellner C. CFTR modulators for the treatment of cystic fibrosis. PT. 2014;39:500–511.
  11. Guimbellot J, Sharma J, Rowe SM. Toward inclusive therapy with CFTR modulators: Progress and challenges. Pediatr Pulmonol. 2017;52(S48):S4–S14.
  12. Gramegna A, Contarini M, Aliberti S, Casciaro R, Blasi F, Castellani C. From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis. Int J Mol Sci. 2020; 21(16): 5882.
  13. Salvatore D, Padoan R, Buzzetti R, Amato A, Giordani B, Ferrari G, Majo F. Patients with cystic fibrosis having a residual function mutation: Data from the Italian registry. Pediatr Pulmonol. 2019;54(2):150-157.
  14. Casciaro R, Costa S, Dang P, Majo F, Ros M. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians. Clin Respir J. 2018 Apr;12(4):1767-1768
  15. Hisert KB, Heltshe SL, Pope C, Jorth P, Wu X, Edwards RM, Radey M, Accurso FJ, Wolter DJ, Cooke G, et al. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections. Am J Respir Crit Care Med. 2017;195(12):1617-1628.
  16. Ronan N, Einarsson GG, Twomey M, Mooney D, Mullane D, NiChroinin M, O’Callaghan G, Shanahan F, Murphy DM, O’Connor OJ, et al. CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor. Chest. 2018;153(2):395-403.
  17. Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D Jr. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation J Cyst Fibros. 2015 Jan;14(1):84-9.
  18. Brody A, Nagle S, Hug C, Marigowda G, Waltz D, Goldin J, Ratjen F, Wang L. S93 Effect of lumacaftor/ivacaftor on total, bronchiectasis, and air trapping computed tomography (ct) scores in children homozygous for f508del-cftr : exploratory imaging substudy. Thorax. 2017;72:A57.
  19. Altes TA, Johnson M, Fidler M, Botfield M, Tustison NJ, Leiva-Salinas C, de Lange EE, Froh D, Mugler JP 3rd. Use of hyperpolarized helium-3 MRI to assess response to ivacaftor treatment in patients with cystic fibrosis J Cyst Fibros. 2017;16(2):267-274.
  20. Davies JC, Wainwright CE,  Sawicki GS,  Higgins MN, Campbell D, Harris C, Panorchan P, Haseltine E, Tian S, Rosenfeld M. Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation: Results of a 2-part Phase 3 clinical trial. Am J Respir Crit Care Med. 2020 Oct 7. doi: 10.1164/rccm.202008-3177OC.
  21. Rubin JL, O’Callaghan L, Pelligra C, Konstan MW, Ward A, Ishak JK, Chandler C, Liou TG. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor. Ther Adv Respir Dis. 2019;13:1753466618820186.
  22. Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S, Simard C, Konstan MW, Sawicki GS, Sewall A, Nyangoma S, et al. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 2018;73(8):731-740